Scarica l'app Stockscreener
5.59
6.48%
0.34
Dopo l'orario di chiusura:
5.26
-0.33
-5.90%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Precedente Chiudi:
$5.25
Aprire:
$5.16
Volume 24 ore:
185.31K
Relative Volume:
0.10
Capitalizzazione di mercato:
$22.75M
Reddito:
-
Utile/perdita netta:
$-54.66M
Rapporto P/E:
-0.2931
EPS:
-19.0729
Flusso di cassa netto:
$-49.98M
1 W Prestazione:
+11.13%
1M Prestazione:
+170.05%
6M Prestazione:
-49.64%
1 anno Prestazione:
+8.33%
Intervallo 1D:
$4.95
$5.7299
Intervallo di 1 settimana:
$3.95
$6.07
Portata 52W:
$1.55
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Nome
Nextcure Inc
Settore
Industria
Telefono
240-399-4900
Indirizzo
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
5.59 | 20.83M | 0 | -54.66M | -49.98M | -19.07 |
VRTX
Vertex Pharmaceuticals Inc
|
484.03 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
772.11 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
875.30 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
197.81 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
329.80 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-03-05 | Aggiornamento | Truist | Hold → Buy |
| 2021-01-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Downgrade | SunTrust | Buy → Hold |
| 2020-06-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-03-24 | Iniziato | The Benchmark Company | Buy |
| 2020-03-02 | Iniziato | ROTH Capital | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-05 | Iniziato | Needham | Buy |
| 2019-11-26 | Iniziato | BTIG Research | Buy |
| 2019-07-09 | Iniziato | BofA/Merrill | Buy |
| 2019-06-03 | Iniziato | Morgan Stanley | Overweight |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Nextcure Inc Borsa (NXTC) Ultime notizie
NXTC|NextCure Inc|Price:5.200|Chg%:+0.960 - TradingKey
NextCure Inc (NXTC) Cash Flow - TradingKey
NextCure Inc (NXTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NextCure Inc (NXTC) Balance Sheet - TradingKey
NextCure Inc (NXTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NextCure Inc (NXTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NXTC|NextCure Inc|Price:5.090|Chg%:+0.850 - TradingKey
NextCure Inc (NXTC) Income Statement - TradingKey
NextCure, Inc. Revenue Breakdown – MUN:2US0 - TradingView
NextCure Inc (NXTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB - Finansavisen
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? - Finansavisen
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB - Carroll County Mirror-Democrat
NextCure announces reverse merger with privately held Avere - MSN
Hansoh takes newco route to globalize IL-23 asset - BioWorld News
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders - GlobeNewswire
Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private Placement - Legal Desire Media and Insights
NextCure Inc. (NXTC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NextCure Inc. (NXTC) Faces Continued Pressure, Testing Key Support LevelsElliott Wave Entry - dars.gov.et
NextCure and Avere Therapeutics Announce Merger and $320 Million Private Financing - Global Legal Chronicle
NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan - Stock Titan
Nextcure transforms into Avere as investors back oral psoriasis therapy - MSN
NextCure Announces Transformative All-Stock Merger With Avere - The Globe and Mail
H.C. Wainwright reiterates NextCure stock rating on merger news By Investing.com - Investing.com Australia
NextCure (NXTC) Slides As Avere Merger Triggers Legal Scrutiny - StocksToTrade
H.C. Wainwright reiterates NextCure stock rating on merger news - Investing.com
Beltsville's NextCure merging with San Francisco startup - The Business Journals
Dow Falls Over 100 Points Following Inflation Data; Crude Oil Gains - Sahm
H.C. Wainwright Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $20 - Moomoo
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC) - Sahm
NextCure, Avere Therapeutics enter definitive merger agreement - TipRanks
HK Stock Market Movement | Hansoh Pharmaceutical (03692) Rises Over 4% After Securing Global Exclusive License with Avere for IL-23; Avere to Merge into NextCure - 富途牛牛
Law firm investigates if NextCure shareholders get a fair price in merger with Avere Therapeutics. - Pluang
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether - GlobeNewswire
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders - GlobeNewswire Inc.
Avere, NextCure Merge To Take AVR-001 Ahead In Psoriasis, Ulcerative Colitis - insights.citeline.com
After $5 billion-plus Novo Nordisk buyout, this biotech band is playing an encore with big merger plans - The Business Journals
Power Moves: NXTC, TOON, SHPH, COCH Entry Points Ignite on Major Catalysts - FinancialContent
Why Did NextCure Stock 3X In One Session?NextCure (NASDAQ:NXTC) - Benzinga
Law firm investigates NextCure merger fairness as shareholders get 1.21% stake in combined company - Pluang
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
NextCure, Inc. (NXTC) Stock: Soars 218% After Avere Merger and $320M Private Placement Deal - parameter.io
NextCure stock surge puts cash payout and 1.21% Avere stake under the lens - TechStock²
NextCure faces investigation over merger terms with Avere Therapeutics amid shareholder concerns. - Pluang
NextCure and Avere Therapeutics Announce $320M Merger to Advance Once-Weekly Oral IL-23 Therapy for Psoriasis and Ulcerative Colitis 12 – Minichart - Minichart
Shareholder Alert: Ademi LLP Investigates Whether NextCure, Inc. Is Obtaining a Fair Price for Public Shareholders - Moomoo
Trending Stocks Today | NextCure Surges 221.55% - Moomoo
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders - lincolnjournal.com
NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan - Quiver Quantitative
NextCure backs Avere merger with $320 million financing - grafa.com
Nextcure Inc Azioni (NXTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nextcure Inc Azioni (NXTC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Jul 31 '26 |
Buy |
4.94 |
36,303 |
179,375 |
722,419 |
| ADAR1 Capital Management, LLC | 10% Owner |
Jul 27 '26 |
Buy |
5.00 |
7,798 |
38,985 |
383,456 |
| ADAR1 Capital Management, LLC | 10% Owner |
Jul 28 '26 |
Buy |
4.95 |
6,400 |
31,677 |
389,856 |
| ADAR1 Capital Management, LLC | 10% Owner |
Jul 29 '26 |
Buy |
5.00 |
3,410 |
17,050 |
393,266 |
1.19%
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):